Get the Stockscreener App
13.78
3.50%
-0.50
After Hours:
13.69
-0.09
-0.65%
Intellia Therapeutics Inc stock is traded at $13.78, with a volume of 3.23M.
It is down -3.50% in the last 24 hours and down -7.08% over the past month.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$14.28
Open:
$13.84
24h Volume:
3.23M
Relative Volume:
0.72
Market Cap:
$1.60B
Revenue:
$52.86M
Net Income/Loss:
$-480.19M
P/E Ratio:
-2.9382
EPS:
-4.6899
Net Cash Flow:
$-421.82M
1W Performance:
+9.02%
1M Performance:
-7.08%
6M Performance:
+20.67%
1Y Performance:
+26.89%
1-Day Range:
$13.57
$14.29
1-Week Range:
$12.40
$14.30
52-Week Range:
$5.90
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
13.78 | 1.65B | 52.86M | -480.19M | -421.82M | -4.6899 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-11-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-28-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-27-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-27-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Apr-21-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-05-25 | Initiated | H.C. Wainwright | Buy |
| Feb-28-25 | Downgrade | Goldman | Neutral → Sell |
| Feb-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
A Look At Intellia Therapeutics (NTLA) Valuation After Earnings Beat Trial Progress And FDA Hold Lift - simplywall.st
Earnings call transcript: Intellia Therapeutics beats Q4 2025 forecasts - Investing.com India
Intellia Therapeutics Inc earnings beat by $0.13, revenue topped estimates - Investing.com UK
INTELLIA THERAPEUTICS ($NTLA) Releases Q4 2025 Earnings - Quiver Quantitative
Intellia Therapeutics Q4 and Full-Year 2025 Financial Results - TradingView
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - Intellia Therapeutics
Responsive Playbooks and the NTLA Inflection - Stock Traders Daily
Earnings Preview For Intellia Therapeutics - Benzinga
Intellia Therapeutics (NTLA) Set to Announce Q4 Earnings - GuruFocus
Intellia Therapeutics Hits Day High with 7.44% Surge in Stock Price - Markets Mojo
Intellia Therapeutics Opens with 6.49% Gain, Outperforming S&P 500's 0.69% Rise - Markets Mojo
Intellia Therapeutics to Announce Q4 Earnings on February 26 - Intellectia AI
Leerink Global Healthcare Conference - Intellia Therapeutics
TD Cowen 46th Annual Health Care Conference - Intellia Therapeutics
Barclays 28th Annual Global Healthcare Conference - Intellia Therapeutics
How to watch Intellia’s March investor talks at three healthcare conferences - Stock Titan
Commit To Purchase Intellia Therapeutics At $10, Earn 32% Using Options - Nasdaq
What's in Store for These 5 Medical Companies This Earnings Season? - TradingView
Take the Zacks Approach to Beat the Markets: Intellia, Colgate-Palmolive, Getty in Focus - Nasdaq
Vestmark Advisory Solutions Inc. Has $5.14 Million Stock Position in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Jupiter Asset Management Ltd. Invests $23.52 Million in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics, Inc. (NTLA) Stock Analysis: 82.95% Potential Upside Captures Investor Attention - DirectorsTalk Interviews
Is Intellia Therapeutics Inc. a top pick in the sectorMarket Growth Review & Daily Price Action Insights - mfd.ru
Intellia Therapeutics to Host Conference Call on February 26, 2026, to Discuss Q4 and Full-Year 2025 Financial Results - Quiver Quantitative
to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business UpdatesIntellia Therapeutics - Intellia Therapeutics
Intellia Therapeutics Fourth Quarter and Full-Year 2025 Financial Results Call - Intellia Therapeutics
Intellia Therapeutics to Hold Conference Call to Discuss - GlobeNewswire
GSA Capital Partners LLP Decreases Holdings in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics (NTLA) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Will Middlefield Banc Corp outperform its industry peersQuarterly Portfolio Report & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Intellia earnings in focus after FDA lifts CRISPR therapy hold By Investing.com - Investing.com South Africa
Intellia earnings in focus after FDA lifts CRISPR therapy hold - Investing.com
A Look At Intellia Therapeutics (NTLA) Valuation After Recent Share Price Momentum And Pipeline Expectations - Yahoo Finance
Clinical Hold Lifted On MAGNITUDE-2 Reshapes Intellia Gene Editing Risk Profile - Yahoo Finance
KalVista (KALV) and Intellia (NTLA) Lead Short Interest Surge in Small-Cap Biotech - GuruFocus
Most and least shorted healthcare stocks with up to $2B market cap - Seeking Alpha
Short Covering: What is Intellia Therapeutics Incs TAM Total Addressable MarketWeekly Trend Recap & Reliable Intraday Trade Alerts - baoquankhu1.vn
H.C. Wainwright Boosts Intellia (NTLA) Price Target After MAGNITUDE-2 Hold Lifted - Finviz
Understanding the Setup: (NTLA) and Scalable Risk - Stock Traders Daily
Did FDA’s MAGNITUDE-2 Clearance and Safety Focus Just Reframe Intellia Therapeutics' (NTLA) Risk Profile? - Sahm
13 Best Innovative Stocks to Buy According to Wall Street Analysts - Insider Monkey
Is Intellia Therapeutics Inc. (38I) stock a contrarian opportunityJuly 2025 Intraday Action & Stock Portfolio Risk Control - mfd.ru
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
Intellia Therapeutics (NTLA) Investor Outlook: Exploring a 105% Potential Upside in Gene Editing Innovations - DirectorsTalk Interviews
Is Intellia Therapeutics Inc. stock trending bullishJuly 2025 Volume & High Accuracy Investment Entry Signals - mfd.ru
What margin trends mean for Intellia Therapeutics Inc. stockJuly 2025 Drop Watch & Consistent Income Trade Ideas - mfd.ru
Will Intellia Therapeutics Inc. stock reach Wall Street targets2025 Biggest Moves & Daily Profit Maximizing Tips - mfd.ru
Should you avoid Intellia Therapeutics Inc. stock right nowJuly 2025 Selloffs & AI Powered Market Entry Ideas - baoquankhu1.vn
A Look At Intellia Therapeutics (NTLA) Valuation After FDA Lifts Clinical Hold On Key Phase 3 Trial - Sahm
Gene Editing Market Growth in Future Scope 2026-2033| CRISPR - openPR.com
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Intellia Therapeutics Inc Stock (NTLA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schultes Birgit C | EVP, Chief Scientific Officer |
Jan 05 '26 |
Sale |
9.21 |
8,508 |
78,359 |
98,533 |
| BASTA JAMES | EVP, General Counsel |
Jan 05 '26 |
Sale |
9.21 |
10,397 |
95,756 |
101,528 |
| Cohen Fred E | Director |
Jan 05 '26 |
Buy |
9.35 |
150,000 |
1,402,500 |
207,453 |
| Lebwohl David | EVP, Chief Medical Officer |
Jan 05 '26 |
Sale |
9.21 |
11,903 |
109,627 |
121,249 |
| Clark Eliana | EVP, Chief Technical Officer |
Jan 05 '26 |
Sale |
9.21 |
9,515 |
87,633 |
87,118 |
| Dulac Edward J III | EVP, Chief Financial Officer |
Jan 05 '26 |
Sale |
9.21 |
6,379 |
58,751 |
99,683 |
| Dube Michael P | VP, Chief Accounting Officer |
Jan 05 '26 |
Sale |
9.21 |
2,989 |
27,529 |
52,277 |
| LEONARD JOHN M | President and CEO |
Dec 11 '25 |
Option Exercise |
6.83 |
49,959 |
341,220 |
1,127,074 |
| LEONARD JOHN M | President and CEO |
Dec 12 '25 |
Option Exercise |
6.83 |
8,557 |
58,444 |
1,047,485 |
| LEONARD JOHN M | President and CEO |
Dec 11 '25 |
Sale |
9.49 |
88,146 |
836,384 |
1,038,928 |
1.18%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):